Publications by authors named "Salut Colell"
Article Synopsis
- * Researchers explored dual-targeting strategies by combining anti-CD19 and anti-BCMA CAR-T cells to enhance effectiveness, optimizing various co-transduction methods and demonstrating improved targeting of tumor cells with the new approach, ARI0003.
- * A first-in-human trial (CARTD-BG-01, NCT06097455) has been launched to assess the safety and efficacy of ARI0003, which was manufactured under strict conditions to lower the risk of genotoxicity.
Chimeric antigen receptor (CAR)-T cell therapy for solid tumors faces significant hurdles, including T-cell inhibition mediated by the PD-1/PD-L1 axis. The effects of disrupting this pathway on T-cells are being actively explored and controversial outcomes have been reported. Here, we hypothesize that CAR-antigen affinity may be a key factor modulating T-cell susceptibility towards the PD-1/PD-L1 axis.
View Article and Find Full Text PDF